Recent News & Disruption in the Space:- July 2026 Eli Lilly and Companys Retatrutide Phase III Trials Gain Massive Momentum: Mid-2026 updates show that Eli Lilly's blockbuster-in-waiting, retatrutide (a triple GIP/GLP-1/glucagon receptor agonist), is fast-tracking through its TRIUMPH-2 Phase III trial for Type 2 Diabetes, aiming to significantly eclipse existing dual-agonist outcomes
Headaches triggered by hunger or low blood sugar may feel more acute and tend to ease after eating
The bacteriostatic agent, typically 0.9% benzyl alcohol, prevents microbial growth during the multi-use period of a nasal spray device
Month 12: approaching maximum effect The STEP 1 trial showed that average weight loss approached its nadir around week 60, roughly month 15
Clinical Pharmacology & Therapeutics
After a median follow-up of 104 weeks, treatment with tirzepatide was associated with a significant reduction in the risk of adjudicated death from cardiovascular causes or a worsening heart failure event (hazard ratio (HR) = 0.62
